BioRestorative Therapies, Inc.
BRTX
$1.57
-$0.04-2.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 247.62% | 161.54% | 175.03% | 189.55% | 35.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 247.62% | 161.54% | 175.03% | 189.55% | 35.49% |
| Cost of Revenue | 409.23% | -- | -- | -- | -- |
| Gross Profit | 241.35% | 140.87% | 155.83% | 170.58% | 30.43% |
| SG&A Expenses | -22.12% | -34.28% | -43.19% | -43.04% | -40.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.72% | -7.71% | -22.19% | -25.87% | -28.60% |
| Operating Income | -1.45% | 9.58% | 24.08% | 27.55% | 29.05% |
| Income Before Tax | -183.12% | -121.20% | 13.81% | -34.20% | 77.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -183.12% | -121.20% | 13.81% | -34.20% | 77.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -183.12% | -121.20% | 13.81% | -34.20% | 77.20% |
| EBIT | -1.45% | 9.58% | 24.08% | 27.55% | 29.05% |
| EBITDA | -1.25% | 9.91% | 24.50% | 27.97% | 29.46% |
| EPS Basic | -360.63% | -17.60% | 59.07% | 30.80% | 93.73% |
| Normalized Basic EPS | -284.67% | -0.74% | 66.48% | 30.80% | 93.73% |
| EPS Diluted | -355.59% | -17.26% | 59.11% | 30.93% | 93.66% |
| Normalized Diluted EPS | -284.67% | -0.74% | 66.48% | 30.80% | 93.73% |
| Average Basic Shares Outstanding | 38.64% | 65.15% | 84.08% | 74.29% | 61.33% |
| Average Diluted Shares Outstanding | 38.64% | 65.15% | 84.08% | 74.29% | 61.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |